Drugs / Laptisor de matca activat
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06756711 | Dec 2024 → Sep 2025 overdue | autism spectrum disorder | Fundatia Bio-Forum | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Laptisor de matca activat | “The supplements tested consist of three products - a combination of apitherapy and plant extracts - which have been approved for sale as individual supplements for more than 5...” NCT06756711 ↗ |
| Known as | Royal Jelly | “The supplements tested consist of three products - a combination of apitherapy and plant extracts - which have been approved for sale as individual supplements for more than 5...” NCT06756711 ↗ |